Miroslav Reljanovic

Miroslav Reljanovic

Miroslav Reljanovic: A Comprehensive Analysis of His Innovations and Achievements

Miroslav Reljanović, a medical doctor and board-certified neurologist, has made significant contributions to the field of neurology over the years.

As a physician in a large World Health Organisation (WHO) collaborating centre in Zagreb, Croatia, he has been a clinical investigator in several Phase II and III studies. Dr. Reljanović has also been a consultant to various pharmaceutical companies, bringing his expertise to new developments in the industry.

Dr. Reljanović is best known for founding Ergomed, a Contract Research Organisation (CRO) that has become a leading company in its field.

His experience and accomplishments throughout his career have been essential in shaping the course of Ergomed – now a prominent player in the world of pharma and biotech.

He has contributed greatly to the development of clinical trial processes, risk and quality management, and work in specific therapeutic sectors, making a lasting impact in the lives of many patients.

Key Takeaways

  • Dr. Miroslav Reljanović, a renowned neurologist, has been actively involved in clinical studies and pharmaceutical consultancy.
  • As the founder of Ergomed, he has played a pivotal role in its growth and development, establishing it as a leading CRO.
  • His work has influenced various aspects of pharmaceutical research, from clinical trial processes to risk and quality management.

Career and Contributions

Miroslav Reljanovic 1

Role at Ergomed

Dr. Miroslav Reljanović is the founder of both Ergomed and PrimeVigilance Ltd.. He currently serves as the Executive Chairman of Ergomed Plc and Co-Managing Director at ERGOMED Center for Data Management & Statistics GmbH. With extensive experience in clinical research and neurology, Reljanović has been an integral part of Ergomed’s growth and continued success.

Innovations in Drug Development

Under Dr. Miroslav Reljanović’s leadership, Ergomed has been instrumental in introducing innovative approaches to drug development. They have strived to enhance operational efficiency and improve patient outcomes, setting new standards within the industry.

Clinical Research Contributions

Dr. Reljanović, a board-certified neurologist, has been involved as a clinical investigator in several Phase II and III studies in the field of neurology. While working as a physician in a large WHO collaborating centre in Zagreb, Croatia, he contributed significantly to clinical research and was a consultant to various pharmaceutical companies.

During his time at Ergomed, Dr. Reljanović has focused on improving the study site coordination model and played a key role in the continuous development of Ergomed’s management and operational execution.

His knowledge and experience in clinical development have contributed greatly to the company’s growth and recognition as a leading player in the field of clinical research.

Ergomed Overview

Miroslav Reljanovic 3

Services Offered

Ergomed PLC is a global provider of specialised services to the pharmaceutical industry. They offer a wide range of solutions, including Clinical Research Outsourcing and Pharmacovigilance. In 2008, Ergomed co-founded PrimeVigilance, a major specialist provider of pharmacovigilance services, which received the Queen’s Award for Enterprise in 2014 and 2019.

Geographical Presence

Ergomed has an extensive global footprint, providing services across the United Kingdom, Rest of Europe, Middle East, Africa, North America, Asia, and Australia. This widespread presence enables Ergomed to efficiently cater to the diverse needs of pharmaceutical companies worldwide.

Key Personnel

Ergomed boasts an experienced team of professionals, led by Dr. Miroslav Reljanovic, the company’s founder and a board-certified neurologist. The management team includes:

  • Chief Financial Officer (CFO): Responsible for overseeing the financial aspects of the company
  • Chief Operating Officer (COO): Ensures the smooth functioning of day-to-day operations
  • Non-Executive Director: Provides guidance on strategic direction and corporate governance
  • Head of Quality and Regulatory: Ensures compliance with industry standards and regulations
  • President of North America: Oversees Ergomed’s operations in North America
  • Executive Director of Global Clinical Operations: Leads clinical operations on a global scale
  • Ergomed Head of Site Management: Coordinates the management of clinical study sites
  • Ergomed Head of Business Development: Explores new business opportunities and fosters partnerships
  • Chief Commercial Strategy Officer: Develops and implements commercial strategies to drive growth
  • President of Clinical Research: Guides the company’s clinical research projects and activities
  • President of PrimeVigilance: Leads the PrimeVigilance division, focusing on pharmacovigilance services
  • Chief Commercial Officer: Directs and manages the company’s overall commercial activities

Ergomed’s team of experts is dedicated to providing exceptional services to the pharmaceutical industry and contributing to the development of new drugs. With their comprehensive solutions, the company continues to deliver results that exceed client expectations.

Financial Highlights

Miroslav Reljanovic 5

Stock Performance

Ergomed, founded by Miroslav Reljanovic in 1997, is a life science company providing various services, from project management to clinical trials. Since its inception in Zagreb, Croatia, the company has shown consistent growth.

Ergomed was listed on the London Stock Exchange and subsequently on the AIM Market. Financial tracking websites, such as Wallmine, provide an overview of how the stock has performed over the years, with Miroslav Reljanovic’s net worth reaching £120 million after a private equity swoop. During the first half of 2023,

the firm reported revenue of £76.7 million, up 10% compared to the previous year. Additionally, their order book reached £310 million, indicating a 9% increase in demand for the company’s services.

Acquisitions and Expansions

In an effort to expand its operations and increase its market presence, Ergomed has executed strategic acquisitions throughout its years of operation.

Two noteworthy instances exemplifying the company’s expansion include the deal that valued Ergomed at £703.1 million and set it on a course to leave the London stock market.

Furthermore, the company’s strong financial performance, coupled with successful Sec and IPO ventures, have enhanced its reputation in the industry.

Through carefully planned acquisitions and expansions, Ergomed has strengthened its position in the life science market, effectively contributing to the company’s impressive stock performance.

Among its various endeavours, Ergomed’s commitment to research and development in the field of neurology continues to be bolstered by Dr. Miroslav Reljanovic’s expertise as a board-certified neurologist. As a result, Ergomed is well-positioned for continued growth and success in the coming years.

PrimeVigilance Services

Miroslav Reljanovic 7

PrimeVigilance, established in 2008 by Dr. Miroslav Reljanovic and Dr. Elliot Brown, is an Ergomed Group company that provides comprehensive and high-quality pharmacovigilance and medical information services. This section will discuss the company’s pharmacovigilance services and medical information services in more detail.

Pharmacovigilance Services

PrimeVigilance offers a wide range of pharmacovigilance services to the pharmaceutical, biotechnology, and medical device industries. These services include drug safety monitoring throughout the product lifecycle, such as preclinical, clinical trials, and post-approval stages.

Their highly experienced team provides end-to-end solutions, from case processing and safety database management to regulatory reporting. PrimeVigilance’s expert staff ensures that their clients’ pharmacovigilance needs are met in a timely and cost-effective manner.

They are well-versed in international regulatory requirements, allowing them to help companies meet the necessary standards for drug safety in various regions.

Medical Information

In addition to pharmacovigilance services, PrimeVigilance also specialises in medical information services.

They provide professional support for healthcare professionals and patients, ensuring accurate and up-to-date information is available about their clients’ products.

Their services include handling inquiries, providing medical writing, and developing standard response documents.

PrimeVigilance’s experienced staff can also support product launches and create tailored solutions to meet clients’ unique medical information needs, such as educational materials, scientific articles, and conference materials.

By utilising their medical information services, companies can ensure that healthcare professionals are well-informed about their products, ultimately leading to improved patient safety and optimised medical outcomes.

Clinical Trial Processes

Miroslav Reljanovic 9

Dr. Miroslav Reljanović has an extensive background in clinical research, particularly in the field of neurology. As a physician at a large WHO collaborating centre in Zagreb, Croatia, he has been involved in numerous Phase II and III clinical trials, which has provided him with valuable experience in the various aspects of clinical trial processes.

Clinical trial planning is a crucial part of the process. It involves setting objectives, designing a study protocol, and establishing a schedule to ensure that the research is conducted in a controlled and ethical manner.

Dr. Reljanović’s expertise in neurology aided in formulating hypotheses, selecting suitable endpoints, and defining appropriate sample sizes – all critical elements of planning a trial.

Effective trial management ensures that clinical trials are executed smoothly and efficiently. Dr. Reljanović’s experience in managing studies extends to coordinating with various stakeholders, such as sponsors, ethics committees, and regulatory authorities.

Additionally, he has played a significant role in managing budgets and resources, whilst adhering to the Good Clinical Practice (GCP) guidelines to maintain the highest level of safety and data integrity.

In clinical trials, study site coordination is essential for achieving consistent results across multiple locations. Dr. Reljanović has been adept at fostering communication with site staff, providing them with the necessary training and ensuring compliance with study protocols.

Consequently, this has led to better monitoring of patient enrolment, data collection, and overall trial management.

Monitoring and evaluating clinical research is another integral aspect of clinical trial processes.

This involves overseeing the progress of a trial, managing risk, and ensuring that endpoints are met. Dr. Reljanović’s comprehensive understanding of these various components has enabled him to identify, address, and mitigate potential issues throughout the trial lifecycle.

In summary, Dr. Miroslav Reljanović’s accomplishments in clinical research have given him a well-rounded perspective on clinical trial processes.

His wealth of experience in trial planning, management, and coordination has undoubtedly contributed to his reputation as a successful neurologist and clinical investigator in the field of medicine.

Specific Therapeutic sector work

Miroslav Reljanovic 11

Dr Miroslav Reljanović, a medical doctor and board-certified neurologist, has made significant contributions in various therapeutic areas.

His expertise spans across multiple fields, including neurology, oncology, haematology, allergy, respiratory, neurology/CNS, and orphan drugs.

During his time as a physician in a large WHO collaborating centre in Zagreb, Croatia, Dr Reljanović served as a clinical investigator in several Phase II and III studies in the field of neurology. His involvement in these studies showcased his deep understanding of neurological disorders and central nervous system (CNS) conditions.

Throughout his career, Dr Reljanović has also been a consultant to various pharmaceutical companies. His guidance and insights have been invaluable to these organisations as they develop and advance treatments for complex diseases in numerous therapeutic areas.

In addition to his work in neurology and CNS, Dr Reljanović has delved into the world of oncology and haematology. His investigation of treatments for cancer and blood disorders demonstrates his commitment to the ongoing fight against these severe conditions.

Furthermore, Dr Reljanović has made contributions to the fields of allergy and respiratory diseases. By working on novel treatments and approaches, he has helped improve the lives of countless patients who suffer from allergies, asthma, and various respiratory conditions.

Finally, Dr Reljanović’s interest in orphan drugs emphasises his dedication to addressing rare diseases that often lack proper treatment options. His extensive work in developing and promoting treatments for these underserved populations reflects his passion for providing patients with the best possible care.

In summary, Dr Miroslav Reljanović’s work covers a wide range of therapeutic sectors, showcasing his versatility and commitment to improving the medical landscape.

His expertise in neurology, pharmaceuticals, oncology, haematology, allergy, respiratory, CNS, and orphan drugs has made a significant impact in each respective field.

Awards and Achievements

Miroslav Reljanovic 13

Dr Miroslav Reljanovic, a prominent figure in the pharmaceutical industry, has garnered significant recognition for his professional accomplishments and contributions.

As the co-founder of PrimeVigilance, his impressive work earned him the esteemed Queen’s Award for Enterprise in both 2014 and 2019. This award highlights his company’s exceptional dedication to excellence in pharmacovigilance services, a vital component of the pharmaceutical sector.

In addition to the prestigious Queen’s Award, Dr Reljanovic’s leadership skills were further demonstrated when he successfully guided Ergomed through its Initial Public Offering (IPO) on the AIM market of the London Stock Exchange in 2014.

Under his watch, the company experienced noteworthy growth and completed several acquisitions, solidifying its position within the industry.

Throughout his storied career, Dr Miroslav Reljanovic has proven himself to be a resilient and innovative leader. As the founder of Ergomed Plc and PrimeVigilance Ltd, his efforts have significantly shaped the landscape of pharmacovigilance and the pharmaceutical world as a whole.

His perseverance undoubtedly positions him amongst the movers and shakers in this diverse and exciting field.

Frequently Asked Questions

Miroslav Reljanovic 15

Who is Miroslav Reljanovic?

Miroslav Reljanovic is a medical doctor and a board-certified neurologist. He has extensive experience in clinical research and has worked as a consultant to various pharmaceutical companies. As a physician in a large WHO collaborating centre in Zagreb, Croatia, he was involved in several Phase II and III studies in the field of neurology.

What is his background in medicine?

Dr. Reljanovic completed his medical degree and went on to specialise in neurology. His work as a neurologist has provided valuable insight and expertise to the pharmaceutical industry, including successful involvement in clinical trials and consultations with pharmaceutical companies.

What is Miroslav’s role in Ergomed?

Miroslav Reljanovic is the founder and Executive Chairman of Ergomed PLC. He established the company in 1997 and has played a critical role in its growth and development. Under his leadership, Ergomed focuses on delivering innovative solutions in drug development and clinical research.

What is Ergomed’s focus area in research?

Ergomed is dedicated to providing specialised services in drug development and clinical research. The company operates across various therapeutic fields, with a particular emphasis on oncology, neurology, and orphan diseases. Ergomed’s services include clinical trial management, pharmacovigilance, and medical information services to support the pharmaceutical industry.

What are the achievements of Miroslav Reljanovic?

Dr. Reljanovic’s most notable achievement is the founding and growth of Ergomed PLC. Through his leadership, the company has expanded its services and become a recognised name within the pharmaceutical industry. Miroslav’s involvement in clinical research and contributions to the field of neurology have also been significant components of his career.

Has he published any articles or research papers?

While it is clear that Dr. Miroslav Reljanovic has contributed to the field of neurology and made substantial accomplishments within clinical research, specific information regarding published articles or research papers may not be readily available from the provided search results.


Notice: ob_end_flush(): Failed to send buffer of zlib output compression (1) in /home/rainmak1/public_html/wp-includes/functions.php on line 5420

Notice: ob_end_flush(): Failed to send buffer of zlib output compression (1) in /home/rainmak1/public_html/wp-includes/functions.php on line 5420